<DOC>
	<DOCNO>NCT00158028</DOCNO>
	<brief_summary>The purpose study determine efficacy risperidone compare placebo treatment psychotic-like deficit symptom schizotypal personality disorder ( SPD ) . Treatment risperidone , 5HT2 dopamine D2 blocking agent , hold particular promise treatment SPD . Unlike traditional antipsychotic , risperidone target deficit negative symptom schizophrenia . The deficit-like symptom SPD therefore also likely respond treatment risperidone . One common complication present psychopharmacologic treatment SPD traditional neuroleptic fact many patient discontinue treatment due medication-induced dysphoria . Given initial report serotonergic component risperidone mechanism , risperidone anticipate produce little dysphoria .</brief_summary>
	<brief_title>Risperidone Treatment Psychotic-like Deficit Symptoms Schizotypal Personality Disorder</brief_title>
	<detailed_description>All patient receive comprehensive medical evaluation prior participation study , part normal clinical care . The evaluation include extensive medical history , physical examination , laboratory evaluation include SMA-18 , CBC differential , TFT 's , U/A , stool guaiac , serology , drug screen , chest X-ray ( indicate ) , EKG , , woman , pregnancy test . [ Note : Subjects consent procedure separate consent , `` Biological Correlates Personality Disorder- Information Subjects ( 88244 ) '' , invite join study . ] Patients interviewed clinical psychology doctoral student train use structured instrument ass Axis I Axis II pathology . A rater independently complete either Schedule Affective Disorders Schizophrenia ( SADS ) ( Spitzer &amp; Endicott 1978 ) , modify evaluation DSM-IV criterion Axis 1 disorder , Structured Clinical Interview DSM-IV Axis I Disorders ( First et al 1996 ) Structured Interview DSM-III-R Personality Disorders ( SIDP-R ) ( Pfohl et al 1989 ) also modify evaluation DSM-IV criterion . When possible , information gather independently informant ( first degree relative life-long friend ) supplement information obtain clinical interview review past record . The use structure interview , questionnaire part standard clinical care . PART 1 Part 1 single-blind two-week placebo washout . Patients see weekly research psychiatrist . One week ( placebo ) medication dispense time research program physician direct supervision Dr. Koenigsberg . Patients see weekly throughout study . Interviews assessment standardize identical throughout phase study . They include Clinical Global Impression scale ( CGI ) , Scale Assessment Negative Symptoms ( SANS ) , Positive Negative Symptom Scale ( PANSS ) , Hamilton Depression Rating Scale ( HDRS ) , administered weekly . At baseline 4- 9-weeks treatment , subject also receive series paper-and-pencil computer-presented cognitive test ( DOT test , Paced Auditory Serial Addition Task , Continuous Performance Task-Identical Pairs version , Serial Verbal Learning Test Wechsler memory Scale-Revised Visual Reproduction test ) . No medication , study drug , allow protocol . If , two-week placebo washout period , total SANS score decrease 35 % great , patient enter Phase 2 . Use placebo washout part standard clinical care . PART 2 Part 2 double blind , 9-week parallel-arm placebo-controlled portion study . Randomization conduct Pharmacy . One week medication ( active placebo ) dispense time research program physician direct supervision Dr. Koenigsberg . The patient receive 1 tablet PO QD every day study . If enrol Active Arm study , patient receive .25 mg risperidone tablet orally daily Days 1 7 ; .5 mg risperidone tablet orally daily Days 8 21 ; 1 mg risperidone tablet orally daily Days 22-35 ; 1.5 mg risperidone tablet orally daily day 36-49 ; 2 mg risperidone orally daily day 50 63 . If treating psychiatrist believe high dose clinically indicate , physician may alter increase dose 2 mg per day begin day 22 4 mg per day begin day 50 . Weekly visit include standard assessment review protocol compliance . Treatment risperidone part current standard clinical care schizotypal personality disorder study design establish usefulness population . Similarly use double bind placebo control part standard clinical care . PART 3 Patients randomize placebo arm Part 2 offer opportunity participate 8 week open label study risperidone otherwise identical Part 2 . Data analyze repeated measure analysis variance separately score CGI , SANS , PANSS , HDSR compare placebo active medication .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Personality Disorders</mesh_term>
	<mesh_term>Schizotypal Personality Disorder</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Schizotypal Personality Disorder Over 65</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Schizotypal Personality Disorder</keyword>
	<keyword>Risperidone</keyword>
	<keyword>Treatment</keyword>
	<keyword>Cognitive</keyword>
</DOC>